Its expertise will be used in what’s called an extension study to allow people living with Huntington's to continue to contribute to the search for a treatment for the condition. IXICO’s involvement will generate a further £500,000 in revenues.
“The announcement emphasises our partner-of-choice status in neurodegenerative data analytics and our capabilities across all stages of clinical development," said chief executive Giulio Cerroni.
In a note to clients, analysts at ‘house’ broker Shore Capital commented: “The extension is further evidence of IXICO’s momentum in Huntington’s disease, having agreed four new contracts for the condition in its last financial year, including a £9.1mln agreement for a pivotal Phase III trial announced in September.”
In afternoon trading, IXICO shares eased back after hitting an early session high of 32p, losing a penny at 29.50p.
-- Adds analyst comment, share price --